LFS Crystals to be used in Trial PET Scanning Device

Japanese Positron Emission Tomography Manufacturer Orders Additional Patented LFS Scintillation Crystals For Use in Trial PET Scanning Device

Singapore, February 19, 2013 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has received an additional order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from a positron emission tomography (PET) original equipment manufacturer (OEM) based in Japan. The LFS scintillation crystals are to be installed in a PET Crystal Module and used in a trial PET scanning device. This is a follow-up order to previously announced trial orders received from a PET OEM and a radiation detection OEM based in Japan. The PET Crystal Module units are also used in PET medical scanners manufactured in South Korea.

“Having our patented LFS scintillation crystals tested in an actual OEM’s PET scanning device is a significant milestone in the commercialization of this advanced technology,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “The scientific team from the Japanese manufacturer was very impressed by the performance of our LFS scintillation crystals and will now be using them in a scanning simulation. These scintillation crystalswere the first batch produced by our strategic partner, the Beijing Opto-Electronics Technology Company, and the quality of the very fast and very bright material is of the highest degree. This is a clear indication that Zecotek is in the position to provide new customers with a reliable supply of scintillation material that is a cost competitive and patent secure. We are very pleased with these developments.”

Zecotek’s patented (US patent No. 7,132,060) LFS series of scintillation crystals are distinguished by their high light yields and ultra-fast decay times, which allow for faster and higher-resolution operation of medical and industrial imaging devices. The Company’s manufacturing processes and technologies permit the growth of very large-diameter boules with uniform properties and without cracks (a problem with many other competing scintillation materials) resulting in high element output and lower unit costs. Furthermore, Zecotek’s line of LFS crystals covers a wide range of emission wavelengths which can be tailored to match the spectral sensitivity of various photo detectors including Zecotek’s solid-state MAPD photo detector arrays.

-30-

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanner technologies, 3D auto-stereoscopic displays, fiber lasers and waveguide micro lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisional companies: Zecotek Imaging (medical, industrial and research), Zecotek Lasers (industrial and research) and Zecotek 3D (monitors for multimedia, entertainment, industrial and medical). The Company has labs located in Canada, Singapore and Russia, with affiliated R&D and production facilities in USA, China, and South Korea. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances with multinational OEMs, distributors and other industry leaders. For more information, visit www.zecotek.com.

This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

For Additional Information Please Contact:

Zecotek Photonics Inc.

Michael Minder
T: (604) 783-8291
[email protected]

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

print